Works matching IS 01676997 AND DT 2022 AND VI 40 AND IP 1

Results: 25
    1

    Author Correction: Antineoplastic activity of products derived from cellulose‑containing materials: levoglucosenone and structurally‑related derivatives as new alternatives for breast cancer treatment.

    Published in:
    2022
    By:
    • Delbart, Damian Ignacio;
    • Giri, German Francisco;
    • Cammarata, Agostina;
    • Pan, Melisa Denise;
    • Bareño, Lizeth Ariza;
    • Amigo, Natalia Loreley;
    • Bechis, Andrés;
    • Suarez, Alejandra Graciela;
    • Spanevello, Rolando Ángel;
    • Villaverde, Marcela Solange;
    • Todaro, Laura Beatriz;
    • Urtreger, Alejandro Jorge
    Publication type:
    Correction Notice
    2

    Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.

    Published in:
    Investigational New Drugs, 2022, v. 40, n. 1, p. 124, doi. 10.1007/s10637-021-01184-5
    By:
    • Dev, Rony;
    • Zhong, Linda L.;
    • Zarifa, Abdulrazzak;
    • Albittar, Aya A.;
    • Rubin, Laura;
    • Liu, Suyu;
    • Yap, Timothy A.;
    • Dalal, Shalini;
    • Hui, David;
    • Karp, Daniel D.;
    • Tsimberidou, Apostolia M.;
    • Piha-Paul, Sarina A.;
    • Ahnert, Jordi Rodon;
    • Fu, Siqing;
    • Meric-Bernstam, Funda;
    • Naing, Aung
    Publication type:
    Article
    3
    4
    5
    6
    7

    A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma.

    Published in:
    Investigational New Drugs, 2022, v. 40, n. 1, p. 134, doi. 10.1007/s10637-021-01170-x
    By:
    • Ahn, Daniel H.;
    • Uson Junior, Pedro Luiz Serrano;
    • Masci, Peter;
    • Kosiorek, Heidi;
    • Halfdanarson, Thorvardur R.;
    • Mody, Kabir;
    • Babiker, Hani;
    • DeLeon, Thomas;
    • Sonbol, Mohamad Bassam;
    • Gores, Gregory;
    • Smoot, Rory;
    • Bekaii-Saab, Tanios;
    • Mahipal, Amit;
    • Mansfield, Aaron;
    • Tran, Nguyen H.;
    • Hubbard, Joleen M.;
    • Borad, Mitesh J.
    Publication type:
    Article
    8
    9
    10
    11
    12
    13

    A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma.

    Published in:
    Investigational New Drugs, 2022, v. 40, n. 1, p. 81, doi. 10.1007/s10637-021-01164-9
    By:
    • Babiker, Hani;
    • Schlegel, Peter J.;
    • Hicks, Lee G.;
    • Bullock, Andrea J.;
    • Burhani, Nafisa;
    • Mahadevan, Daruka;
    • Elquza, Emad;
    • Borad, Mitesh J.;
    • Benaim, Ely;
    • Peterson, Christine;
    • Heaton, Callie;
    • Ocean, Allyson J.
    Publication type:
    Article
    14
    15

    Antineoplastic activity of products derived from cellulose-containing materials: levoglucosenone and structurally-related derivatives as new alternatives for breast cancer treatment.

    Published in:
    Investigational New Drugs, 2022, v. 40, n. 1, p. 30, doi. 10.1007/s10637-021-01167-6
    By:
    • Delbart, Damian Ignacio;
    • Giri, German Francisco;
    • Cammarata, Agostina;
    • Pan, Melisan Denise;
    • Bareño, Lizeth Ariza;
    • Amigo, Natalia Loreley;
    • Bechis, Andrés;
    • Suarez, Alejandra Graciela;
    • Spanevello, Rolando Ángel;
    • Villaverde, Marcela Solange;
    • Todaro, Laura Beatriz;
    • Urtreger, Alejandro Jorge
    Publication type:
    Article
    16

    In vitro selection of DNA aptamers against human osteosarcoma.

    Published in:
    Investigational New Drugs, 2022, v. 40, n. 1, p. 172, doi. 10.1007/s10637-021-01161-y
    By:
    • Tsogtbaatar, Khaliunsarnai;
    • Sousa, Diana A.;
    • Ferreira, Debora;
    • Tevlek, Atakan;
    • Aydın, Halil Murat;
    • Çelik, Eda;
    • Rodrigues, Ligia
    Publication type:
    Article
    17
    18
    19
    20

    In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).

    Published in:
    Investigational New Drugs, 2022, v. 40, n. 1, p. 68, doi. 10.1007/s10637-021-01156-9
    By:
    • Meneses-Lorente, Georgina;
    • Fowler, Stephen;
    • Guerini, Elena;
    • Kowalski, Karey;
    • Chow-Maneval, Edna;
    • Yu, Li;
    • Mercier, Francois;
    • Ullah, Mohammed;
    • Umehara, Kenichi;
    • Brink, Andreas;
    • Buchheit, Vincent;
    • Zwanziger, Elke;
    • Phipps, Alex;
    • Djebli, Nassim
    Publication type:
    Article
    21
    22
    23
    24

    Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.

    Published in:
    Investigational New Drugs, 2022, v. 40, n. 1, p. 163, doi. 10.1007/s10637-021-01143-0
    By:
    • Taugner, Julian;
    • Käsmann, Lukas;
    • Karin, Monika;
    • Eze, Chukwuka;
    • Flörsch, Benedikt;
    • Guggenberger, Julian;
    • Li, Minglun;
    • Tufman, Amanda;
    • Reinmuth, Niels;
    • Duell, Thomas;
    • Belka, Claus;
    • Manapov, Farkhad
    Publication type:
    Article
    25